What is Pluristem?
Headquartered in Haifa, Israel, Pluristem Therapeutics Inc. operates at the intersection of advanced biotechnology and clinical research. The company specializes in the development of placental expanded (PLX) cell therapy products, which are engineered to treat a diverse range of ischemic, inflammatory, and hematologic conditions. With a robust portfolio that includes Phase III clinical trials for hip fracture recovery and ongoing investigations into acute respiratory distress syndrome, Pluristem maintains a strong market position. Their collaborative efforts, including high-profile research with NASA's Ames Research Center, demonstrate a commitment to pushing the boundaries of cellular therapy in both terrestrial and extraterrestrial medical applications.
How much funding has Pluristem raised?
Pluristem has raised a total of $199M across 14 funding rounds:
Other Financing Round
$250K
Other Financing Round
$1.2M
Grant
$4.2M
Grant
$2.9M
Stock Offering
$17M
Grant
$3.3M
Share Placement
$30M
Multiple Rounds
$49M
Stock Offering
$20M
Debt
$56.2M
Share Placement
$15M
Other Financing Round (2010): $250K, investors not publicly disclosed
Other Financing Round (2010): $1.2M, investors not publicly disclosed
Grant (2014): $4.2M supported by Israeli Ministry of Economy, Office of the Chief Scientist
Grant (2015): $2.9M featuring Israeli Ministry of Economy, Office of the Chief Scientist
Stock Issuance/Offering (2015): $17M, investors not publicly disclosed
Grant (2016): $3.3M with participation from Israeli Ministry of Economy, Office of the Chief Scientist
Share Placement (2016): $30M led by Innovative Medical Management
Stock Issuance/Offering (2017): $17.3M, investors not publicly disclosed
Grant (2017): $8.7M featuring Horizon 2020 Program
Grant (2017): $7.9M backed by Horizon 2020 Program
Stock Issuance/Offering (2017): $15.1M, investors not publicly disclosed
Stock Issuance/Offering (2019): $20M, investors not publicly disclosed
Debt (2020): $56.2M supported by European Investment Bank
Share Placement (2020): $15M, investors not publicly disclosed
Key Investors in Pluristem
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
Horizon 2020 Program
A major research and innovation funding program by the European Union designed to secure Europe's global competitiveness in science and technology.
Israeli Ministry of Economy, Office of the Chief Scientist
A government body dedicated to fostering industrial research and development within Israel to drive economic growth and technological advancement.
What's next for Pluristem?
With the recent influx of capital, Pluristem is strategically positioned to scale its manufacturing capabilities and expedite its late-stage clinical trials. The company's roadmap focuses on the commercialization of its PLX-PAD and PLX-R18 platforms, aiming to transition from research-heavy development to market-ready therapeutic solutions. Future growth will likely be driven by the successful completion of ongoing Phase III trials and the expansion of international licensing agreements, particularly in key markets like South Korea. As the company matures, the focus will shift toward regulatory approval milestones and the integration of its cell therapy technologies into standard clinical practice, solidifying its role as a leader in the regenerative medicine landscape.
See full Pluristem company page
